Clinical trial

"Multicenter Observational Study to Assess the Incidence and Features of COVID-19 and the Response to COVID-19 Vaccination in Fragile Patients"

Aliases
NCT05222139, ORCHESTRA-4
Name
ORCHESTRA-4
Description
The present study is part of ORCHESTRA project, a three-year international research project aimed at tackling the coronavirus pandemic. ORCHESTRA provides an innovative approach to learn from the pandemic SARS-CoV-2 crisis, derive recommendations to further management of COVID-19 and be prepared for the possible future pandemic waves. The ORCHESTRA project aims to deliver sound scientific evidence for the prevention and treatment of the infections caused by SARS-CoV-2 assessing epidemiological, clinical, microbiological, and genotypic aspects of population, environment and socio-economic features. The project builds upon existing, and new largescale population cohorts in Europe (France, Germany, Spain, Italy, Belgium, Romania, Netherlands, Luxemburg, and Slovakia) and non-European countries (India, Perú, Ecuador, Colombia, Venezuela, Argentina, Brazil and Gabon) including SARS-CoV-2 infected and non-infected individuals of all ages and conditions. The primary aim of ORCHESTRA is the creation of a new pan European cohort applying homogenous protocols for data collection, data sharing, sampling, and follow-up, which can rapidly advance the knowledge on the control and management of the COVID-19. ORCHESTRA will include SARS-CoV-2-negative individuals and thereby enable a prospective follow-up and an analysis of vaccination response. The cohort will involve four different populations: general population, COVID-19 patients, fragile individuals (children, elderly, transplanted, oncological, HIV infected, and those with Parkinson disease), and health-care workers. Each of these "perpetual" cohorts can answer different research questions and vaccine strategies. Within the ORCHESTRA project, the Work Package 4 (WP4) will focus on the cohort of fragile patients including pregnant women/new-born, children, patients with HIV infection, patients with autoimmune disease, solid organ transplant recipients, patients with oncological and hematological diseases, patients with cystic fibrosis, patients with Parkinson Disease and rheumatological diseases from from 14 countries (5 European and 9 non-European countries), with approximately 20000 subjects.
Trial arms
Trial start
2021-05-24
Estimated PCD
2023-07-16
Trial end
2024-11-30
Status
Active (not recruiting)
Treatment
COVID-19 vaccination
Monitoring COVID-19 vaccination
Arms:
Children, Patients with Parkinson Disease, Patients with cystic fibrosis, Patients with hematological diseases, Patients with oncological diseases, Patients with rheumatological diseases, People living with HIV, Pregnant women/ New-borns, Solid organ transplant recipients
Size
8894
Primary endpoint
Early immune response to COVID-19 vaccine patients
3 ± 1 month after vaccination onset
Late immune response to COVID-19 vaccine
12 ± 3 months after vaccination onset
Rate of COVID-19 breakthrough infections
within 1 year after vaccination onset
Rate of hospital admission for COVID-19 breakthrough infections condition and its impact on the outcome in fragile patients
within 1 year after vaccination onset
Rate of death for COVID-19 breakthrough infections patients
within 1 year after vaccination onset
Eligibility criteria
Inclusion Criteria: * Any age * Any comorbidity * Person (or attorney or deputy who has been authorized to make the decision for patients who lack capacity) consent to participate or appropriate local waiver of consent. Exclusion Criteria: * Patients did not agree to participate
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'biological samples (including blood, naso-pharingeal swabs, urine, and stool) will be collected and stored in the biobank of each participating center according to local authority regulation.'}, 'enrollmentInfo': {'count': 8894, 'type': 'ACTUAL'}}
Updated at
2024-08-28

1 organization

1 product

3 indications

Indication
COVID-19
Indication
Vaccination